Dramatisation of the impact of a HIV diagnosis and starting treatment with Triumeq
TRIUMEQ is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40 kg. 
Before initiating treatment with abacavir-containing products, HLA-B*5701 status must always be documented. Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to the risk of hypersensitivity reaction.
Based on pooled data from Phase IIb and Phase III clinical studies, the most frequently reported adverse reactions considered possibly or probably related to dolutegravir and abacavir/lamivudine were; Nausea (12%), Insomnia (7%), Dizziness (6%) and Headache (6%).
To learn more about Triumeq, please visit